

(51) International Patent Classification:
C07K 14/755 (2006.01)(21) International Application Number:
PCT/US2020/013722(22) International Filing Date:
15 January 2020 (15.01.2020)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
62/793,058 16 January 2019 (16.01.2019) US(71) Applicants: **BAXALTA INCORPORATED** [US/US];
1200 Lakeside Drive, Bannockburn, IL 60015 (US). **BAX-
ALTA GMBH** [CH/CH]; Zächlerweg 4, 6300 Zug (CH).(72) Inventors: **ROTTENSTEINER, Hanspeter**; Haidgasse
10/17, Vienna, 1020 (AU). **SCHEIFLINGER, Friedrich**;
Michelbeuerngasse 4/17, Vienna, 1090 (AU).(74) Agent: **ANTCZAK, Andrew J.** et al.; Morgan, Lewis &
Bockius LLP, One Market, Spear Street Tower, San Fran-
cisco, CA 94105 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).(54) Title: VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE
THERAPY OF HEMOPHILIA A

Figure 11

(57) Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*